Federal grants to Progenra Inc
Progenra Inc in Malvern, Pennsylvania received $1.4 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Diabetes, Digestive, and Kidney Diseases Extramural Research, with $535,600. In fiscal 2025 it was awarded $302,421.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$1.4 million
- Awards5
- Awarded in FY 2025$302,421
- Largest award$302,421
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $265,978 |
| FY 2022 | 2 | $551,493 |
| FY 2023 | 0 | $0 |
| FY 2024 | 1 | $269,622 |
| FY 2025 | 1 | $302,421 |
Programs that fund Progenra Inc
| Program | Awards | Amount |
|---|---|---|
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 2 | $535,600 |
| Allergy and Infectious Diseases Research | 1 | $302,421 |
| Cardiovascular Diseases Research | 1 | $296,932 |
| Arthritis, Musculoskeletal and Skin Diseases Research | 1 | $254,561 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $1.4 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Ubiquitin pathway modulators as novel antituberculosis drugs - new approaches are needed to treat niaid priority pathogens, including mycobacterium tuberculosis (MTB). Emerging drug-resistance in mtb poses a significant threat to global health, generating a pressing need to develop innovative therap | Allergy and Infectious Diseases Research | May 16, 2025 | $302,421 |
| Parkin activators for cardioprotective therapies - myocardial infarction followed by left ventricular remodeling is the leading cause of heart failure (HF). Current therapies are inadequate to modulate adverse remodeling and prevent subsequent cardiac failures. As such there is a critical unmet need | Cardiovascular Diseases Research | March 30, 2022 | $296,932 |
| Ubiquitin pathway modulators for treating pancreatitis - new approaches are needed to treat acute and chronic pancreatitis which is a major health problem in the us. One novel approach is to promote mitochondrial health to protect pancreas from damages caused by various stressors. We have identified | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 19, 2024 | $269,622 |
| Novel txnip degraders for treating diabetes - more than 30 million american have diabetes (~10% of the population), making it a major health issue. Available therapies for diabetics include insulin replacement or various drugs that modulate insulin production/sensitivity or reduce blood sugar levels | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 5, 2021 | $265,978 |
| Development of itch-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis - the INTERLEUKIN-1 receptor-activated kinase 4 (IRAK4) is a serine/threonine kinase mediating the innate immune and inflammatory response; it is expressed in numerous cell type | Arthritis, Musculoskeletal and Skin Diseases Research | September 1, 2022 | $254,561 |
Questions people ask
How much federal grant money does Progenra Inc get?
$1.4 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Progenra Inc the most?
The Department of Health and Human Services, with $1.4 million in 5 awards.
What is Progenra Inc's largest federal grant?
$302,421 under Allergy and Infectious Diseases Research, with its first action in the period on May 16, 2025. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Progenra Inc?
Its largest are Diabetes, Digestive, and Kidney Diseases Extramural Research, Allergy and Infectious Diseases Research and Cardiovascular Diseases Research.
Other grant recipients in Malvern
Largest federal grant recipients in Pennsylvania · Federal grants in Pennsylvania